This content is machine translated Invitation to the 12th IBD Roadshow | June 23-25, 2025 | with Professor Bruce Sands Acceleration in IBD Treatment: How early and holistic care leads to better outcomes We cordially invite you to the 12th IBD Roadshow from June 23-25, 2025! The internationally renowned expert Professor Bruce Sands (Icahn School of Medicine, Mount Sinai, New York, USA) is...…
View Post 5 min This content is machine translated Sponsored Content: UEGW update: Post-hoc analyses of the SEQUENCE study Risankizumab is convincing compared to ustekinumab [1] The SEQUENCE comparative study recently published in the New England Journal of Medicine (NEJM) compared the two interleukin (IL)-23 and IL-12/-23 inhibitors risankizumab (SKYRIZI®) and ustekinumab in Crohn’s disease (CD)…
View Post 4 min This content is machine translated Sponsored Content: Crohn's disease Biomarkers underline superiority of risankizumab compared to ustekinumab in Crohn’s disease [1] In the SEQUENCE study, risankizumab was compared with ustekinumab for the treatment of Crohn’s disease (CD) in patients who had failed anti-TNF therapies. Biomarkers such as fecal calprotectin (FC) and…
View Post 5 min This content is machine translated Sponsored Content: United European Gastroenterology Week (UEGW) 2023 Risankizumab demonstrates superiority compared to ustekinumab in Crohn’s disease [1] Data from the current SEQUENCE study was presented at the United European Gastroenterology Week (UEGW), which took place from October 14 to 17, 2023, and has since been published [1,2].…
View Post 6 min This content is machine translated 11th Swiss IBD Roadshow “Curing mucosa is our major goal” The meanwhile 11th Swiss IBD Roadshow (10. – 12. June 2024) took place this year under the title “ADVANCED THERAPIES IN IBD – TOWARDS A NEW SEQUENCE”. Between his lectures…
